The BioNTech SE ADR BNTX rallied 1.59% to $117.64 Thursday, on what proved to be an all-around favorable trading session for ...

The BioNTech SE ADR BNTX inched 0.49% higher to $118.22 Friday, on what proved to be an all-around mixed trading session for ...

Fintel reports that on September 24, 2024, Morgan Stanley upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

The decision not to advance the vaccine into Phase III trials effectively ends GSK's ambition to bring the first HSV vaccine ...

Health Canada recently asked provinces and territories to get rid of their older COVID-19 vaccines to ensure the most current ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger. | ...